CMS Open Payments · Program Year 2024
SprintRay Inc
SprintRay Inc reported $106,848.90 across General Payments, Research, and Ownership to 225 physicians and teaching hospitals across 225 transactions.
- $106.8K Below-median payer
- All-tracks total
- 225 Above-median volume
- Transactions
- 225 Above-median reach
- Recipients
- −$194.2K
- General Payments vs PY2023
SprintRay Inc reported $106,848.90 across all CMS Open Payments tracks (General + Research + Ownership) to 225 physicians and teaching hospitals in Program Year 2024 - ranking #1167 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $106,848.90, averaging $474.88 per recipient.
How SprintRay Inc's $106.8K all-tracks total breaks down
SprintRay Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
11/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer sprintray-inc SprintRay Inc
$106.8K · #1167/1,925 · 0.0% industry · PY2024
- TOT $106.8K
- RANK #1167
- SHARE 0.0%
- TXN 225
- RCP 225
- CAT 4
- GEN $106.8K
- ΔGEN −$194.2K
- TOP1 20.9%
- PY 2024
Volume peers
Nearest volume peer: Orpyx Medical Technologies Inc. ($107.0K)
SprintRay Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
SprintRay Inc's CMS-reported General Payments decreased by $194.2K (−64.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SPRINTRAY INCPY2023: SPRINTRAY INCPY2024: SprintRay Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $301,022.09
- PY2024
- $106,848.90
What the Data Shows for SprintRay Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For SprintRay Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Honoraria" at $58.6K, accounting for 54.8% of this company's General Payments and 25 transactions.
General Payment Breakdown by Type
SprintRay Inc made 4 types of general payments. "Honoraria" is the largest category at $58.6K, 54.8% of General Payments.
SprintRay Inc reports 4 general-payment categories - the top three are Honoraria (54.8%), Compensation for Services Other Than Consulting (30.0%), and Food and Beverage (13.6%). The remaining 1 category make up 1.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How SprintRay Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $58.6K | 25 | 54.8% |
| Compensation for Services Other Than Consulting | $32.1K | 12 | 30.0% |
| Food and Beverage | $14.5K | 186 | 13.6% |
| Travel and Lodging | $1.7K | 2 | 1.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $58,492.70 (54.7%) of $106,848.90 in this company's General Payments records across 185 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for SprintRay Inc
The five named recipients with the highest reported General Payments from this company
- 1
Diana M Tadros
$22,287.57 across 4 reported transactions
- 2
Andrew C Johnson
$18,163.43 across 6 reported transactions
- 3
Joshua K Nagao
$8,727.69 across 2 reported transactions
- 4
Celin Eduardo Arce
$5,625.00 across 2 reported transactions
- 5
Shant Aharonian
$3,689.01 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
SprintRay Inc's spend rank (#1167 of 1,925, bottom 39% by spend) and concentration rank (#1,068 of 1,838, bottom 42% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- EDW Pharma, Inc. : $2.6K total payments, HHI 916
- Onkos Surgical, Inc. : $402.3K total payments, HHI 915
- Kinex Medical Company LLC : $133.04 total payments, HHI 915
- Choice Spine, LLC : $1.0M total payments, HHI 912
- SOMAVAC Medical Solutions, Inc. : $2.8K total payments, HHI 906
- Ares Trading SA : $254.3K total payments, HHI 902
- SprintRay Inc (this company) : $106.8K total payments, HHI 897
- Siemens Medical Solutions USA, Inc. : $13.3M total payments, HHI 895
- Hyhte Holdings Inc. : $1.3M total payments, HHI 892
- Nuo Therapeutics : $833.09 total payments, HHI 891
- Motiva USA, LLC : $482.1K total payments, HHI 886
- Zambon USA Ltd. : $62.5K total payments, HHI 886
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as SprintRay Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about SprintRay Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with SprintRay Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Microgenics Corporation
Swing Therapeutics, Inc.
Nxstage Medical, Inc.
Neoss, Inc.
Nucletron Operations B.V.
Put this to use
SprintRay Inc ranks #1167 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just SprintRay Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.